Abstract:OBJECTIVE:To investigate the dynamic quantitative changes in expression of hepatitis B virus (HBV) surface antigen (HBsAg) that occurs during the natural recovery course and the short-term antivirus treatment period of patients suffering from flares in chronic hepatitis B (CHB).METHODS:CHB patients presenting for treatment of flare-ups were randomly assigned to receive treatment with Entecavir antiviral (group A, n = 39) or to naturally resolve the acute condition (group B, n = 22). All patients MELD scores were calculated and HBsAg levels and HBV DNA loads were measured upon admission (baseline), at worst-condition stage, and end of treatment/flare-up (discharge). Pairwise comparisons of intergroup differences were made to evaluate the change in the three disease parameters over time in response to the management approach.RESULTS:The levels of HBsAg were not significantly different between the two groups at baseline, worst-condition stage and discharge (group A: (3.68+/-0.45), (3.84+/-0.19) and (3.69+/-0.58) log10 cut-off index (COI) respectively; group B: (3.59+/-0.54), (3.47+/-0.76) and (3.43+/-0.68) log10 COI respectively; all P more than 0.05). However, the HBV DNA loads were significantly lower in group A than in group B at the worst-condition stage and at discharge (all P less than 0.05). In group A, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant. Also in group A, the HBV DNA load showed a gradually decreasing trend over time (baseline more than worst-condition stage more than discharge, all P less than 0.05). No significant differences were observed over time in the HBsAg levels of group A. In group B, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant (P = 0.619). Also in group B, the HBV DNA loads were significantly higher at baseline and worst-condition stage than at discharge (P = 0.000 and P = 0.003 respectively), but the difference between baseline and worst-condition stage was not significant. Finally, no significant differences were observed over time in the HBsAg levels of group B.CONCLUSION:Natural recovery from an acute flare-up of CHB is not accompanied by a change in HBsAg levels. In addition, short-term antiviral treatment to resolve the flare-up has no influence on HBsAg level.

Blocking Role of Glucocorticoid in the Course of Hepatitis B to Deteriorate

Glucocorticoid versus traditional therapy for hepatitis B virus-related acute-on-chronic liver failure: A systematic review and meta-analysis

Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure

The efficacy of glucocorticoids in treatment of HBV-associated acute-on-chronic liver failure in the early stage

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Effect and Clinical Significance of Glucocorticoid on CD4+CD25+ Regulatory T Cells in Patients with Hepatitis B Virus-Related Pre-Liver Failure

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

[Effect of Glucocorticoid Treatment on the Clinical Outcome of Patients with Early-Stage Liver Failure].

Efficacy and safety of glucocorticoids on patients with severe viral hepatitis:A Meta-analysis

Effects of Reduced Glutathione and Glycyrrhizin on Treatment of Chronic Hepatitis B

T Helper Cell Dysregulation with Hepatitis B and Rebalance with Glucocorticoids

Outcomes of Glucocorticoid Treatment in HBVAssociated Acute-on-Chronic Liver Failure Patients: A Retrospective Observational Study.

Lamivudine Efficacy on the Prevention and Treatment of Hepatitis B Virus Reactivation Induced by Glucocorticoid in Patients with HBV Infection

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

Influence of Antiviral Treatment on the Efficacy and Prognosis of Compensated Hepatitis B Cirrhosis

The Short-Term Efficacy of Small Dosage of Dexamethasone Therapy in Chronic Hepatitis B with Tendency to Severe Hepatitis

Preventive Effects of Antifungal Drugs in Patients with Acute-on-chronic Liver Failure Treated with Glucocorticoid

The impact of hepatotoxic drugs on the outcome of patients with acute deterioration of hepatitis B virus-related chronic disease

The outcome study of rheumatic disease patients with chronic hepatitis B infection